May 29 |
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study
|
May 8 |
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
|
Apr 30 |
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
|
Apr 29 |
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
|
Apr 17 |
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
|
Apr 11 |
ATUS, ATHE and GRFS among pre-market losers
|
Apr 10 |
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
|
Feb 23 |
Alterity Therapeutics drops on capital raise
|
Feb 20 |
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
|
Jan 29 |
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
|